Drug before surgery could slash need for follow-up radiation in prostate cancer
NCT ID NCT03412396
Summary
This study is testing if taking a hormone therapy drug called apalutamide for 6 months before prostate removal surgery can improve outcomes for men with intermediate-risk prostate cancer. The main goal is to see if this pre-surgery treatment reduces certain high-risk features in the removed tissue, which could mean fewer patients need radiation therapy after their operation. Researchers will follow 45 participants to check the drug's safety and see if it lowers cancer recurrence rates.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.